Pfizer ends its quest to develop Alzheimer’s and Parkinson’s drugs … Nearly 70 Wisconsin seniors fear eviction amid Medicaid dispute … Hawaiian program gives family caregivers who...
Also in the news for August 15, 2014 . . .
Aug 15, 2014
High-dose flu vaccine about 25% more effective for seniors … Regular internet use reduces dementia risk in seniors, scientists say … Expert panel recommends seniors receive Pfizer pneumonia...
Pharma companies embrace branding
By
Elizabeth Newman
Mar 01, 2014
Big pharmaceutical companies are exploring “brand personality” in their marketing strategies, according to new research.
Pfizer study reveals pneumonia drug effective for the elderly
Feb 25, 2014
Pfizer Inc. said it is planning on presenting the results of its Community-Acquired Pneumonia Immunization Trial in Adults study next month, and that it may have significant impact on preventing community-acquired...
CompanyBriefs
May 01, 2013
Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury’s previous...
Experimental drug prevents blood clots from forming in legs and lungs
Dec 11, 2012
The experimental drug Eliquis prevented blood clots in the legs and lungs and kept them from recurring, according to a new study. Patients who took the medicine were 81% less likely to have symptoms of...
FDA approves Pfizer’s rheumatoid arthritis treatment
Nov 14, 2012
Federal regulators recently approved Pfizer’s new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from...
Pfizer gets FDA approval for rheumatoid arthritis treatment
By
McKnight's Staff
Nov 09, 2012
Federal regulators approved Pfizer’s new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories’...
Following Hurricane Sandy, drug makers get back to business
Nov 07, 2012
The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about...
Experimental Alzheimer’s drug fails to deliver in closely watched clinical trial
By
McKnight's Staff
Jul 25, 2012
Alzheimer’s researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.